comprised of enterprise business, grew 8. 8% YoY driven by improving sales in both telecom and ICT services as well as CSL’s revenue consolidated since Feb-18. Network OPEX excluding cost of TOT partnership
planning and the improvement in the quality of goods, as well as improving and controlling the internal operational efficiency of the Company. During the second quarter, the Company continued to pursue its
investment last year. The Company recognized share of profit from associates of Baht 19.87 million, improving from share of loss of Baht 5.94 million last year. The share of profit from Krungthai ZMICO
support sales growth as well as business expansion of oversea subsidiaries. In terms of proportion to total revenues, operating and administrative expenses represented 43% of total revenues, improving from
for the launch of the production automation under the scheme of “Delta Smart Manufacturing”. The company believes that it would benefit the company by enhancing energy saving and improving the
compensation rates of medical staff secured for the future business expansion. Financing Costs The Company and its subsidiary’s financing costs in relation to the loans from financial institutions and related
increasing number of out patients. Therefore, the hospital management is focusing on improving the quality of medical services related to non-communicable diseases such cardiovascular disease, neurologic
of dessert cafés, which accounts for the largest share of revenue. The growth in sales of dessert cafés was mainly due to the improving COVID-19 situation, as a result more customers were eating-out
(5.5% of revenue from 10.5% in 2016). Network OPEX was flat QoQ but increased 99% YoY mainly from 4G expansion and addition of TOT partnership payment. EBITDA margin improved to 44.6% from 36.4% in 4Q16